Immune Checkpoint Inhibitor Clinical Trials in Paris
4 recruitingParis, France
Showing 1–4 of 4 trials
Recruiting
Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
ATROPOS: Survival Analysis of ICI-associated Myocarditis
Immune Checkpoint Inhibitor-associated Myocarditis
Groupe Hospitalier Pitie-Salpetriere1,500 enrolled1 locationNCT07633587
Recruiting
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
Immune Checkpoint Inhibitor-Related MyocarditisArrhythmiaLong QT Syndrome
Groupe Hospitalier Pitie-Salpetriere127,000 enrolled1 locationNCT07644715
Recruiting
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
CancerImmune Checkpoint InhibitorCardiovascular Complication+1 more
Institut Mutualiste Montsouris200 enrolled1 locationNCT05799898